Genetron Holdings Ltd. ADR (GTH): Price and Financial Metrics
GTH Price/Volume Stats
| Current price | $0.88 | 52-week high | $1.75 |
| Prev. close | $0.89 | 52-week low | $0.73 |
| Day low | $0.87 | Volume | 5,200 |
| Day high | $0.90 | Avg. volume | 62,004 |
| 50-day MA | $0.94 | Dividend yield | N/A |
| 200-day MA | $0.99 | Market Cap | 80.64M |
GTH Stock Price Chart Interactive Chart >
GTH POWR Grades
- GTH scores best on the Sentiment dimension, with a Sentiment rank ahead of 86.38% of US stocks.
- GTH's strongest trending metric is Sentiment; it's been moving down over the last 83 days.
- GTH ranks lowest in Momentum; there it ranks in the 1st percentile.
GTH Stock Summary
- GTH's went public 2.93 years ago, making it older than merely 15.71% of listed US stocks we're tracking.
- With a year-over-year growth in debt of 84.01%, GENETRON HOLDINGS LTD's debt growth rate surpasses 87.15% of about US stocks.
- GENETRON HOLDINGS LTD's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -94.21%, greater than the shareholder yield of only 6% of stocks in our set.
- If you're looking for stocks that are quantitatively similar to GENETRON HOLDINGS LTD, a group of peers worth examining would be ALIM, CNEY, IMRN, WPRT, and CNTG.
- To dig deeper into the stock's financial statements, go to GTH's page on browse-edgar?action=getcompany&CIK=0001782594.
Genetron Holdings Ltd. ADR (GTH) Company Bio
Genetron Holdings, Ltd. engages in precision oncology. It provides cancer molecular profiling by using technologies in molecular biology and data science to transform cancer treatment. It products and services include diagnosis and monitoring through both LDT and IVD products. Its LDT portfolio consists of both specifically designed focused and comprehensive gene panel testing services. It also develops liver cancer early screening products. The company was founded by Si Zhen Wang, Hai Yan, and Wei Wu He in 2015 and is headquartered in Beijing, China.
Latest GTH News From Around the Web
Below are the latest news stories about GENETRON HOLDINGS LTD that investors may wish to consider to help them evaluate GTH as an investment opportunity.
Genetron Health Regains Compliance With Nasdaq Minimum Bid Price RequirementBEIJING, Jan. 18, 2023 (GLOBE NEWSWIRE) -- Genetron Holdings Limited ("Genetron Health" or the "Company", NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced that the Company had received a notification letter (“Compliance Notice”) from the staff of the Listing Qualifications Department of the Nasdaq Stock Market LLC (“Nasdaq”), dated Jan |
Genetron Health Announces Receipt of Notification from NasdaqBEIJING, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Genetron Holdings Limited ("Genetron Health" or the "Company", NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced that it has received written notification from the staff of the Listing Qualifications Department of the Nasdaq Stock Market LLC (“Nasdaq”) dated October 28, 2022, indicating that fo |
Genetron Health Reports Unaudited Second Quarter 2022 Financial ResultsBEIJING, Oct. 12, 2022 (GLOBE NEWSWIRE) -- Genetron Holdings Limited ("Genetron Health" or the "Company", NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today reported its unaudited financial results for the second quarter ended June 30, 2022. Recent Business Highlights Received College of American Pathologists (CAP) Accreditation for its laboratory |
Genetron Health Announces Appointment of Independent Financial Advisor and Legal Counsel to the Special CommitteeBEIJING, Sept. 02, 2022 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, announced today that the special committee (the “Special Committee”) of the Company’s Board of Directors (the “Board”) has retained Kroll, LLC (operating through its Duff & Phelps Opinions Practice |
Genetron Health Announces Receipt of a Preliminary Non-Binding Proposal to Acquire the CompanyBEIJING, Aug. 22, 2022 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, announced today that its Board of Directors (the “Board”) has received a preliminary non-binding proposal letter dated August 21, 2022 (the “Proposal Letter”) from Mr. Sizhen Wang, co-founder, chair |
GTH Price Returns
| 1-mo | -6.70% |
| 3-mo | -11.46% |
| 6-mo | -14.56% |
| 1-year | -41.72% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -21.43% |
| 2022 | -81.64% |
| 2021 | -56.43% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...